UK's Capital Gains Tax reform attacked

4 February 2008

The BioIndustry Association has criticized a compromise proposal by the UK's Chancellor of the Exchequer, Alistair Darling, for Capital Gains Tax as "failing" to recognize the needs of biotechnology R&D. The government had replaced a tapered CGT tax with a flat rate. The new plan for an "entrepreneurs' relief" might be good for such people, but not for business angels and bioscience investors, BIA chief executive Aisling Burnand warned.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight